VYNE Therapeutics Inc (VYNE)

[realfast95]

FD Disclosure.

On March 30, 2021, VYNE Therapeutics Inc. (the “Company”) updated its investor presentation to include a slide summarizing the payor coverage with respect to AMZEEQ® (minocycline) topical foam, 4%, and ZILXI® (minocycline) topical foam, 1.5%. The Company updated the investor presentation following the decision by CVS Caremark (“Caremark”) to not include these products, and other new branded comparator drugs, on its national formulary for 2021. The slide also reflects the decision by many Caremark custom plans to include the Company’s products on their respective formularies. A copy of the updated investor presentation, including the new slide 20, is attached as Exhibit 99.1 to this current report on Form 8-K.